Aclaris Therapeutics, Inc.

NASDAQ:ACRS

2.51 (USD) • At close February 4, 2025
Bedrijfsnaam Aclaris Therapeutics, Inc.
Symbool ACRS
Munteenheid USD
Prijs 2.51
Beurswaarde 268,617,690
Dividendpercentage 0%
52-weken bereik 0.952 - 5.17
Industrie Diagnostics & Research
Sector Healthcare
CEO Dr. Douglas J. Manion Frcp(C), M.D.
Website https://www.aclaristx.com

An error occurred while fetching data.

Over Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research

Vergelijkbare Aandelen

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

5.12 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

8.89 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.463 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

3.17 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

50.21 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.438 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

14.41 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.49 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)